Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 439.72M | 750.53M | 318.75M | 319.29M | 335.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 439.72M | 750.53M | 318.75M | 319.29M | 335.04M |
| Cost of Revenue | 85.86M | 84.31M | 85.37M | 54.87M | 51.27M |
| Gross Profit | 353.86M | 666.22M | 233.38M | 264.42M | 283.77M |
| SG&A Expenses | 198.12M | 199.18M | 214.69M | 183.66M | 210.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 556.12M | 536.66M | 548.59M | 469.10M | 523.65M |
| Operating Income | -116.40M | 213.87M | -229.83M | -149.81M | -188.61M |
| Income Before Tax | -137.69M | 150.74M | -274.21M | -172.36M | -207.02M |
| Income Tax Expenses | 183.00K | 2.99M | 1.82M | 1.74M | 472.00K |
| Earnings from Continuing Operations | -137.87M | 147.75M | -276.02M | -174.10M | -207.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.87M | 147.75M | -276.02M | -174.10M | -207.49M |
| EBIT | -116.40M | 213.87M | -229.83M | -149.81M | -188.61M |
| EBITDA | -102.92M | 227.20M | -216.65M | -135.74M | -174.30M |
| EPS Basic | -1.10 | 1.18 | -2.21 | -1.40 | -1.68 |
| Normalized Basic EPS | -0.69 | 0.84 | -1.38 | -0.86 | -1.08 |
| EPS Diluted | -1.10 | 1.15 | -2.21 | -1.40 | -1.69 |
| Normalized Diluted EPS | -0.69 | 0.80 | -1.38 | -0.86 | -1.08 |
| Average Basic Shares Outstanding | 125.61M | 125.22M | 124.66M | 124.11M | 123.27M |
| Average Diluted Shares Outstanding | 125.61M | 131.34M | 124.66M | 124.11M | 123.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |